Jan 8 (Reuters) - Johnson & Johnson ( JNJ ) said on

Wednesday that it has temporarily paused the rollout of its

Varipulse heart device in the United States, citing an abundance

of caution as the company investigates four reported stroke

events.

The Varipulse, a pulsed field ablation system, received U.S.

Food and Drug Administration approval in November for treating a

type of abnormal heart rhythm condition.